Tagged with Respiratory

Belgium Fluidda is the world leader in the field of functional respiratory imaging which combines HRCT scans and computational fluid dynamics technology. CEO Jan de Backer outlines the major developments of the Belgian firm’s recent history including expansion into the US, how a USD ten million injection of Series A financing…

Mexico Chiesi Mexico’s Marco Ruggiero discusses his initial impressions of the Mexican pharma market, his strategic priorities for the affiliate, and the increasing importance of the company’s respiratory portfolio in Mexico.   With respiratory diseases, there is sometimes the erroneous perception that they are not as severe or urgent as other…

Sweden Niclas Källbom Karlsson, general manager of GSK Sweden, reflects on his first five years of heading the local affiliate, in which the company has emerged as a leader in the speciality respiratory medicines, vaccines and HIV area. With a new wave of products to be launched, he highlights the importance…

Thailand Thanakorn and Lakana Ounpiyodom of AeroCare highlight their unique positioning in the inhaler niche and how they have grown both their portfolio and facilities through strategic M&A. They share their strong interest in delivering the most innovative products in the field to Thai patients, and their wish to expand across…

China Kai Zhang, founder and chairman, and Sonia Wang, CEO, of Chinese respiratory technology specialist Omni Pharmaceuticals, discuss the respiratory market in China, how Omni plans to introduce four respiratory drugs onto the market within two years, and its focus on innovative new technologies.   Unlike oncology, the inhalation market in…

Malaysia Saravanan G., group managing director of Biocare Group, details the opportunities he identified to create the first MDI (Metered Dose Inhalers) manufacturing plant in Malaysia. He also explains further the support received by the government for his initiatives and how the company will continue its efforts to bring more innovative…

Turkey Two months into the role, Umut Meriç, general manager for Chiesi Turkey, discusses the affiliate’s rapid progression and his plans to ensure Turkish patients benefit from the global company’s latest therapies in the respiratory and rare diseases areas. Meriç underlines the importance of motivating and developing a productive, dynamic and…

Poland Ewa Sek, general manager at ResMed Poland, explains the crucial role of ResMed in raising awareness on sleep apnea, COPD and other respiratory-related conditions in Poland and highlights the important investments that should be made to increase the diagnostics capabilities as well as to reimburse telemedicine and device accessories.  ResMed…

Portugal Salvador Lopez saw an opportunity in the summer of 2015 to create the first Portuguese affiliate for Mundipharma. Three years on, he reveals how their business model, company culture and leadership has succeeded in disrupting the respiratory market with their blockbuster drug Flutiform, built the fastest growing subsidiary in Portugal…

Poland Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore, he highlights the strategic importance of the nation for Chiesi globally, as well as his aspiration to further solidify the…

Colombia Anant Atal, head of Latin America for Cipla, discusses how the establishment of offices in Colombia was facilitated by its longstanding history in the country, the multiple initiatives the company has engaged in with doctors and patients to improve access to treatments in Respiratory, Oncology and HIV, as well as…

Greece Stavros Theodorakis, managing director of Chiesi Greece & Cyprus and vice president of the Hellenic Association of Pharmaceutical Companies (SFEE), pinpoints the factors that successfully carried the company through the Greek crisis, while highlighting co-branding and co-promotion as the key strategies behind Chiesi’s leading position in the domestic respiratory market.…